Recovery of breast cancer invasive ductal carcinoma (luminal B subtype, T2N0M0)

Madam Liu Ying, China, a 64-year-old woman, was diagnosed with right breast cancer invasive ductal carcinoma (luminal B subtype, T2N0M0) following the discovery of a firm mass in the upper outer quadrant of her right breast. Despite having no family history of cancer, she was living with long-standing hypertension and type 2 diabetes, which placed her in a more vulnerable position when facing cancer treatment

She underwent a right radical mastectomy with axillary lymph node dissection in November 2024. Postoperative pathology confirmed a 6.0 × 4.0 × 2.5 cm invasive ductal carcinoma with clear surgical margins and no lymph node involvement. While the surgery was successful, her recovery was complicated by slow wound healing, persistent weakness, and significant discomfort during daily dressing changes. These challenges were further intensified when chemotherapy began, as she experienced appetite loss, sleep disturbance, and overall physical strain. Daily wound dressing was painful, discharge persisted, and her overall strength was noticeably low. Managing cancer recovery while living with long-standing diabetes and hypertension placed enormous strain on her body.

Chemotherapy was initiated as advised, but the side effects quickly became overwhelming. After each cycle, she experienced severe appetite loss, disrupted sleep, weakness, and a slow return to normal function. Her family began to worry, not only about the cancer, but whether her body could continue enduring such aggressive treatment.

It was during this fragile period that ECCT was introduced as a complementary cancer treatment. Instead of adding further stress to her body, ECCT was carefully adjusted to support wound healing and recovery first. The ECCT medical team monitored her closely and increased treatment duration gradually, ensuring her body could tolerate the therapy safely.

What stood out most to her family was that, unlike chemotherapy, ECCT did not worsen her daily condition. There was no added pain, no exhaustion, and no disruption to her already weakened system. As ECCT continued, her surgical wound healed completely, her strength improved, and her appetite and sleep stabilized. She was finally able to recover instead of merely enduring treatment.

After stopping chemotherapy due to intolerable side effects, a lung X-ray revealed a shadow that caused renewed anxiety. However, after two months of consistent ECCT treatment, follow up imaging showed that the shadow had completely disappeared. This outcome gave her and her family renewed confidence, not just relief, but reassurance that her condition is stable from recurrence.

Beyond scans and reports, ECCT gave Ms. Liu Ying something equally important: control and peace of mind. The treatment allowed her to continue addressing cancer risks without compromising her quality of life. For her, ECCT became more than a complementary therapy, it became a preventive safeguard, helping her body remain stable after surgery and during a period of high recurrence concern.

Her experience demonstrates how ECCT can play a meaningful role for patients who cannot tolerate aggressive treatments or who need additional protection during chemotherapy. In her case, ECCT supported recovery, improved daily well-being, and provided continued cancer management when conventional options were no longer suitable.

Her journey reflects a growing reality for many cancer patients: survival is not only about removing tumors, but about choosing treatments that the body can sustain. For Ms. Liu Ying, ECCT offered a path that balanced effectiveness, safety, and quality of life, when she needed it most.